Boehringer Ingelheim’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a ...

Servier isn’t the first drug developer to spot a silver lining in Google Cloud. Ginkgo inked its own five-year partnership in ...

Avacta is stepping up development of its peptide-drug conjugate (PDC), kicking off expansion cohorts in multiple tumor types ...

Take a look back at the biggest stories of the week with Fierce Biotech’s conference's kickoff coverage here | Welcome to day ...

Serina Therapeutics is shedding a subsidiary to start the new year off debt-free. | Serina Therapeutics is shedding a ...

GE HealthCare is launching a new imaging research collaboration with the University of California, San Francisco, aimed at ...

The therapy, dubbed OST-HER2, uses a HER2-bioengineered form of the bacteria Listeria monocytogenes to trigger an immune ...

Neumora Therapeutics’ phase 3 fail was worse than analysts feared. | Neumora Therapeutics’ phase 3 fail was worse than ...

The FDA is elevating a recall from Philips related to one of its wearable outpatient heart monitors, used to help detect ...

A month after halting dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial hypertension ...

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...

Daiichi Sankyo is turning to the German city of Heidelberg for help developing antibodies. The Japanese pharma giant is ...